Literature DB >> 19296227

Targeted delivery systems for oligonucleotide therapeutics.

Bo Yu1, Xiaobin Zhao, L James Lee, Robert J Lee.   

Abstract

Oligonucleotides including antisense oligonucleotides and siRNA are emerging as promising therapeutic agents against a variety of diseases. Effective delivery of these molecules is critical to their successful clinical application. Targeted systems can greatly improve the efficiency and specificity of oligonucleotides delivery. Meanwhile, an effective delivery system must successfully overcome a multitude of biological barriers to enable the oligonucleotides to reach the site of action and access their biological targets. Several delivery strategies based on different platform technologies and different targeting ligands have been developed to achieve these objectives. This review aims at providing a summary and perspective on recent progress in this very active area of research.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19296227      PMCID: PMC2664895          DOI: 10.1208/s12248-009-9096-1

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  79 in total

Review 1.  Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway.

Authors:  Zhong Ming Qian; Hongyan Li; Hongzhe Sun; Kwokping Ho
Journal:  Pharmacol Rev       Date:  2002-12       Impact factor: 25.468

Review 2.  State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.

Authors:  Elias Fattal; Amélie Bochot
Journal:  Int J Pharm       Date:  2008-06-19       Impact factor: 5.875

Review 3.  Pharmacokinetics and biodistribution of nanoparticles.

Authors:  Shyh-Dar Li; Leaf Huang
Journal:  Mol Pharm       Date:  2008-07-09       Impact factor: 4.939

Review 4.  Evolution of phage display: from bioactive peptides to bioselective nanomaterials.

Authors:  Va Petrenko
Journal:  Expert Opin Drug Deliv       Date:  2008-08       Impact factor: 6.648

5.  Molecular imaging study on in vivo distribution and pharmacokinetics of modified small interfering RNAs (siRNAs).

Authors:  Thomas Viel; Raphael Boisgard; Bertrand Kuhnast; Benoit Jego; Karine Siquier-Pernet; Françoise Hinnen; Frédéric Dollé; Bertrand Tavitian
Journal:  Oligonucleotides       Date:  2008-09

6.  An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor.

Authors:  Sumio Chono; Shyh-Dar Li; Christine C Conwell; Leaf Huang
Journal:  J Control Release       Date:  2008-07-13       Impact factor: 9.776

7.  Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels.

Authors:  Antonina S Rait; Kathleen F Pirollo; Laiman Xiang; David Ulick; Esther H Chang
Journal:  Mol Med       Date:  2002-08       Impact factor: 6.354

8.  Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.

Authors:  B Jahrsdörfer; R Jox; L Mühlenhoff; K Tschoep; A Krug; S Rothenfusser; G Meinhardt; B Emmerich; S Endres; G Hartmann
Journal:  J Leukoc Biol       Date:  2002-07       Impact factor: 4.962

9.  Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles.

Authors:  Wen Zhou; Xing Yuan; Annette Wilson; Lijuan Yang; Michael Mokotoff; Bruce Pitt; Song Li
Journal:  Bioconjug Chem       Date:  2002 Nov-Dec       Impact factor: 4.774

10.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

View more
  48 in total

Review 1.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

2.  Microfluidic assembly of lipid-based oligonucleotide nanoparticles.

Authors:  Bo Yu; Jing Zhu; Weiming Xue; Yun Wu; Xiaomeng Huang; L James Lee; Robert J Lee
Journal:  Anticancer Res       Date:  2011-03       Impact factor: 2.480

3.  Polyplex-induced cytosolic nuclease activation leads to differential transgene expression.

Authors:  Rahul Rattan; Sriram Vaidyanathan; Gordon S-H Wu; Anisha Shakya; Bradford G Orr; Mark M Banaszak Holl
Journal:  Mol Pharm       Date:  2013-07-24       Impact factor: 4.939

Review 4.  Delivery materials for siRNA therapeutics.

Authors:  Rosemary Kanasty; Joseph Robert Dorkin; Arturo Vegas; Daniel Anderson
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

Review 5.  In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

Authors:  Yunching Chen; Dong-Yu Gao; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2014-05-22       Impact factor: 15.470

6.  A secretagogue-small interfering RNA conjugate confers resistance to cytotoxicity in a cell model of Sjögren's syndrome.

Authors:  Kaleb M Pauley; Adrienne E Gauna; Irina I Grichtchenko; Edward K L Chan; Seunghee Cha
Journal:  Arthritis Rheum       Date:  2011-10

Review 7.  Non-viral vectors for gene-based therapy.

Authors:  Hao Yin; Rosemary L Kanasty; Ahmed A Eltoukhy; Arturo J Vegas; J Robert Dorkin; Daniel G Anderson
Journal:  Nat Rev Genet       Date:  2014-07-15       Impact factor: 53.242

8.  Topical delivery of siRNA into skin using SPACE-peptide carriers.

Authors:  Ming Chen; Michael Zakrewsky; Vivek Gupta; Aaron C Anselmo; Deborah H Slee; John A Muraski; Samir Mitragotri
Journal:  J Control Release       Date:  2014-01-13       Impact factor: 9.776

Review 9.  Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine.

Authors:  Hui Yi Xue; Shimeng Liu; Ho Lun Wong
Journal:  Nanomedicine (Lond)       Date:  2014-02       Impact factor: 5.307

10.  Antitumoral activity of L-ascorbic acid-poly- D,L-(lactide-co-glycolide) nanoparticles containing violacein.

Authors:  Dorival Martins; Lucas Frungillo; Maristela C Anazzetti; Patrícia S Melo; Nelson Durán
Journal:  Int J Nanomedicine       Date:  2010-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.